These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35034446)

  • 1. Quantitative Measurement of Cytosolic and Nuclear Penetration of Oligonucleotide Therapeutics.
    Deprey K; Batistatou N; Debets MF; Godfrey J; VanderWall KB; Miles RR; Shehaj L; Guo J; Andreucci A; Kandasamy P; Lu G; Shimizu M; Vargeese C; Kritzer JA
    ACS Chem Biol; 2022 Feb; 17(2):348-360. PubMed ID: 35034446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative measurement of cytosolic penetration using the chloroalkane penetration assay.
    Deprey K; Kritzer JA
    Methods Enzymol; 2020; 641():277-309. PubMed ID: 32713526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of Sequence-Penetration Relationships of Antisense Oligonucleotides.
    Batistatou N; Kritzer JA
    Chembiochem; 2023 May; 24(9):e202300009. PubMed ID: 36791388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Challenges in Delivery and Cytosolic Translocation of Therapeutic RNAs.
    Johannes L; Lucchino M
    Nucleic Acid Ther; 2018 Jun; 28(3):178-193. PubMed ID: 29883296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.
    Juliano RL
    Nucleic Acid Ther; 2018 Jun; 28(3):166-177. PubMed ID: 29708838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.
    Juliano RL; Ming X; Carver K; Laing B
    Nucleic Acid Ther; 2014 Apr; 24(2):101-13. PubMed ID: 24383421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell Penetration Profiling Using the Chloroalkane Penetration Assay.
    Peraro L; Deprey KL; Moser MK; Zou Z; Ball HL; Levine B; Kritzer JA
    J Am Chem Soc; 2018 Sep; 140(36):11360-11369. PubMed ID: 30118219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics.
    Deprey K; Batistatou N; Kritzer JA
    Nucleic Acids Res; 2020 Aug; 48(14):7623-7639. PubMed ID: 32644123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing Cell Penetration of Biotherapeutics across Human Cell Lines.
    Batistatou N; Kritzer JA
    ACS Chem Biol; 2024 Jun; 19(6):1351-1365. PubMed ID: 38836425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigating the Cytosolic Delivery of Proteins by Lipid Nanoparticles Using the Chloroalkane Penetration Assay.
    Wang J; Zhang S; Li Y; Xu Q; Kritzer JA
    Biochemistry; 2024 Feb; ():. PubMed ID: 38334719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Site Selective Antibody-Oligonucleotide Conjugation via Microbial Transglutaminase.
    Huggins IJ; Medina CA; Springer AD; van den Berg A; Jadhav S; Cui X; Dowdy SF
    Molecules; 2019 Sep; 24(18):. PubMed ID: 31509944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Oligonucleotides: An Outlook on Chemical Strategies to Improve Endosomal Trafficking.
    Mangla P; Vicentini Q; Biscans A
    Cells; 2023 Sep; 12(18):. PubMed ID: 37759475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The chemistry and biology of oligonucleotide conjugates.
    Juliano RL; Ming X; Nakagawa O
    Acc Chem Res; 2012 Jul; 45(7):1067-76. PubMed ID: 22353142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delivery of RNA Therapeutics: The Great Endosomal Escape!
    Dowdy SF; Setten RL; Cui XS; Jadhav SG
    Nucleic Acid Ther; 2022 Oct; 32(5):361-368. PubMed ID: 35612432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumoral RNA-targeted oligonucleotide therapeutics: The third pillar after small molecule inhibitors and antibodies.
    Taniguchi H; Suzuki Y; Imai K; Adachi Y
    Cancer Sci; 2022 Sep; 113(9):2952-2961. PubMed ID: 35701833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of endocytic recycling and lysosomal fusion sensitizes cells and tissues to oligonucleotide therapeutics.
    Finicle BT; Eckenstein KH; Revenko AS; Anderson BA; Wan WB; McCracken AN; Gil D; Fruman DA; Hanessian S; Seth PP; Edinger AL
    Nucleic Acids Res; 2023 Feb; 51(4):1583-1599. PubMed ID: 36727438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemical Manipulation of the Endosome Trafficking Machinery: Implications for Oligonucleotide Delivery.
    Juliano RL
    Biomedicines; 2021 May; 9(5):. PubMed ID: 34063104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptors, endocytosis, and trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides.
    Juliano RL; Carver K; Cao C; Ming X
    J Drug Target; 2013 Jan; 21(1):27-43. PubMed ID: 23163768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Typical and atypical trafficking pathways of Ad5 penton base recombinant protein: implications for gene transfer.
    Rentsendorj A; Xie J; MacVeigh M; Agadjanian H; Bass S; Kim DH; Rossi J; Hamm-Alvarez SF; Medina-Kauwe LK
    Gene Ther; 2006 May; 13(10):821-36. PubMed ID: 16482205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.